

Behavioral Health Clinical Quality eMeasures Project Technical Expert Panel Kick-Off



Health in the 21st Century

MITRE

Agenda

- **Introductions**
 - Core Team
 - IWG Subgroups
 - MITRE Corporation and Project Staffing
 - Technical Expert Panelists
- **Project Goal**
- **EHR “Meaningful Use” Incentive Program**
- **Behavioral Health eMeasures**
- **TEP Schedule and Topics**
- **Next Steps and Questions**
- **Addenda**
 - eMeasure Titles and Descriptions
 - MU Stage 2 NPRM Proposed Measures



Introductions

Core Team

SAMHSA

- **Westley Clark, MD**
- **Maureen Boyle, PhD (TEP Co-lead)**
- **Ken Salyards**
- **Bob Stephenson**

ONC


- **Jesse James, MD**
- **Kevin Larsen, MD**
- **Lauren Richie (TEP Co-lead)**
- **Anca Tabakova**
- **Kate Tipping**

CMS

- **Carrie Feher**

MITRE

Understanding MITRE and FFRDCs



MITRE Project Team



Maggie Lohnes, RN
TEP Lead



Denise Sun, MS Social Work
TEP Support



Nicole Kemper
CQM Expert



Jocelyn Tafalla
*Project Operations
& Communication
Lead*



Saul Kravitz
*Technical Lead
eSpecification SME*

Subgroup Members – Federal Staff

ALCOHOL (3)		
Last Name	First Name	Agency
Boyle	Maureen	SAMHSA
Corbridge	Ian	HRSA
Cotter	Frances	SAMHSA
Dowling	Gaya	NIH/NIDA
Faden	Vivian	NIH/NIAAA
Forman	Reed	SAMHSA
Harris	Alex	VA
Lide	BJ	NIST
Lowman	Cheryl	NIH
McKnight-Eily	Lela	CDC
Tai	Betty	NIH/NIDA

AUTISM (2)		
Last Name	First Name	Agency
Blum	Alex	NIH
Boyle	Maureen	SAMHSA
Gilotty	Lisa	NIH
Kau	Alice	NIH/NICHD
Kavanagh	Laura	HRSA
Smith	Camille	CDC/ONDIEH/NCBDDD
Rice	Catherine	CDC/ONDIEH/NCBDDD
Wolf	Rebecca	CDC/ONDIEH/NCBDDD

DEPRESSION (6)		
Last Name	First Name	Agency
Alemu	Girma	HRSA
Azrin	Susan	NIH/NIMH
Boyle	Maureen	SAMHSA
Cotter	Fran	SAMHSA
Fehér	Carrie	CMS
Harris	Yael	HRSA
LeFauve	Charlene	SAMHSA
Ross	Alex	HRSA

SUBSTANCE ABUSE (2)		
Last Name	First Name	Agency
Boyle	Maureen	SAMHSA
Dowling	Gaya	NIH/NIDA
Ghitza	Udi	NIH/NIDA
Lee	Jinhee	SAMHSA
Reuter	Nick	SAMHSA
Sivilli	June	ONDCP
Tai	Betty	NIH/NIDA

SUICIDE (2)		
Last Name	First Name	Agency
Boyle	Maureen	SAMHSA
Crosby	Alex	CDC
Grenier	Denise	IHS
Lysell	Katy	VA
McKeon	Richard	SAMHSA
Mullen	Mariquita	HRSA
Weglicki	Linda	NIH/NINR

TRAUMA (0)		
Last Name	First Name	Agency
Boyle	Maureen	SAMHSA
Cotton	Beverly	IHS
DeVoursney	David	SAMHSA
Harvell	Jennie	ASPE
Herne	Mose	IHS
Huang	Larke	SAMHSA
Ross	Alex	HRSA
Salyards	Ken	SAMHSA
Young	Elise	HRSA

Bold = Lead
(#) = High Priority Measures

Technical Expert Panel

Gavin	Bart	University of Minnesota- Hennepin County Medical Center
Rhonda	Beale	Chief Medical Officer @ OptumHealth Behavioral Solutions
Lyndra	Bills	Associate Medical Director for the Northeast Pennsylvania
Gregory	Brown	UPenn
Mady	Chalk	Treatment Research Institute (TRI)
Kate	Comtois	Harborview Medical Center
Geri	Dawson	Autism Speaks
Vincent	Felitte	Kaiser Permanente
Deborah	Garnick	Brandeis U Heller School
Frank	Ghinassi	UPMC
Eric	Goplerud	NORC
Rob	Gore-Langton	EMMES
Constance	Horgan	Brandeis U Heller School
Anna Mabel	Jones	Oxford House, Inc.
Rachel	Kimerling	Veterans Administration

(Continued)

Technical Expert Panel (Continued)

Alex	Krist	Community Physician
Robert	Linblad	EMMES
Cathy	Lord	Institute for Brain Development, NY-Presbyterian Hosp
A Thomas	McLellan	Treatment Research Institute
LaVerne	Miller	Policy Research Associates, Delmar, New York
Daniel	Mullin	UMass MHC
Keris	Myrick	Project Return Peer Support Network
Harold	Pincus	Columbia University
Charlie	Reznikoff	University of Minnesota- Hennepin County Medical Center
Lucy	Savitz	Intermountain Healthcare
Robert	Schwartz	Friends Research Institute
Cheryl	Sharp	National Council for Community Behavioral Healthcare
Morton	Silverman	EDC
Piper	Svensson-Ranallo	University of Minnesota Institute for Health Informatics
Thomas	Swales	MetroHealth System/ Case Western Reserve University
Amy	Wetherby	Florida State University
Charles	Willis	Statewide Peer Wellness Initiative/GA Mental Health Consumer Network



Project Goal and Background

EHR “Meaningful Use” Incentive Program

**2009 American Recovery and Reinvestment Act
(ARRA)**


**Health Information Technology for Economic and
Clinical Health Act (HITECH)**

Provides incentive payment to eligible providers (up to \$44,000 over three years) and hospitals (\$\$\$\$ depending on patient volume) for

“The use of a certified Electronic Health Record:

- ... in a meaningful manner, such as e-prescribing.**
- ... for electronic exchange of health information to improve quality of health care.**
- ... to submit clinical quality and other measures”**

Meaningful Use: Meeting the Needs of Today and Tomorrow



Project Goal

Develop a portfolio of behavioral health (BH) clinical quality measures (CQMs) suitable for inclusion in the EHR incentive program for Meaningful Use (MU) of Health Information Technology (IT)



Project Background

HHS and SAMHSA Leaders advocate for BH Measures in Meaningful Use EHR Incentive Program



BH CQM Workgroups develop CQM Concept list



June 2011: HIT Policy Committee (HITPC) Quality Work Group accepts recommendation to fund BH CQM development




July 2011: HITPC accepts CQM Workgroup recommendation to fund BH CQM development




Sept/Oct 2011: eMeasure Contract executed (with MITRE); Project initiated

Project Background Continued...


July-November 2011: **Phase 1**: 6 Federal BH Domain Subgroups Convened (Alcohol, Substance Use, Depression, Suicide, Trauma and Autism)



December/January 2012: Subgroups identify endorsed BH CQMs for eMeasure development and Technical Expert Panel (TEP) concentration; 'Prioritized List' is approved with Core Team



February 2012: eMeasure Request For Proposals distributed; EHR Stage 2 NPRM released; BH TEP Process initiated



March 2012: **Phase 2**: eMeasure contracts awarded and execution initiated; TEP Nominations continue and Process initiated; Clinical research proposal submitted

Related Federal Behavioral Health Initiatives

- **National Quality Forum (NQF), Behavioral Health Call for Measures**
- **AHRQ/USPSTF**
- **Alignment with NQF, CMS, ONC, AHRQ, HRSA, ASPE, NIH**

Behavioral Health eClinical Quality Measures

Two Phases

- Behavioral Health eMeasure Development
- Behavioral Health Technical Expert Panel



Behavioral Health eMeasures

Measure Selection and Prioritization

■ Process of Measure Identification

- Statement of Work
- IWG and Subgroup identification


■ Prioritization Considerations

1. Measure is NQF endorsed; needs eSpecification
2. Measure has been developed, but needs NQF endorsement and eSpecification
3. Measure available for a specific usage; needs modification and NQF endorsement
 - Changing a measure for EP to EH
 - Changing an adult measure to an adolescent measure
4. Conceptual measures
 - Including new composite measure development


eMeasures and Respective Developers

Measure Developer	No.	Measure No. and Title
CQAIMH (Center for Quality Assessment and Improvement for Mental Health)	3	<ul style="list-style-type: none"> • #0109, Bipolar Disorder and Major Depression: Assessment for Manic or Hypomanic Behaviors • #0110, Bipolar Disorder and Major Depression: Appraisal for Alcohol or Chemical Substance Use • #0111, Bipolar Disorder: Appraisal for Risk of Suicide
HRSA (OHSU) (Health Services and Resources Administration)	1	<ul style="list-style-type: none"> • #1385, Developmental Screening Using a Parent Completed Screening Tool (Parent report, Children 0-5)
NCQA (National Committee for Quality Assurance)	4	<ul style="list-style-type: none"> • #0576, Follow-Up After Hospitalization for Mental Illness • #1401, Maternal Depression Screening • \$1406, Risky Behavior Assessment or Counseling by Age 13 • #1507, Risky Behavior Assessment or Counseling by Age 18
Resolution Health, Inc. part of WellPoint	1	<ul style="list-style-type: none"> • #0580, Bipolar Antimanic Agent
TJC (The Joint Commission)	2	<ul style="list-style-type: none"> • #1661, SUB-1 Alcohol Use Screening • #1663, SUB-2 Alcohol Use Brief Intervention Provided or Offered and SUB-2a Alcohol Use Brief Intervention

MITRE eMeasure Preparation Process



Current eMeasure Preparation Process for Meaningful Use




eMeasure Development Schedule

All Subcontractors

eMeasure Developers

Value Set Developer



❖ Hand-offs noted in Orange



Behavioral Health Technical Expert Panel

Project Phase 2 – Outcomes

- **Broad review of 6 domain areas with report of findings**
 - Perform Environmental Scan for non-NQF-endorsed measures
 - Perform Clinical Literature Search for available evidence
 - TEP Review of Environmental Scan results
 - Measure Development Recommendations Report

- **Research Drug Use/ Prescription Drug Misuse (DU/PDM) Clinical Evidence**
 - Document clinical evidence related to primary care based screening and brief treatment for DU/PDM
 - Document clinical evidence related to primary care based SBIRT screening and brief treatment for DU/PDM
 - Fund clinical research of patient-reported SISQ

- **Support development of a trended Depression Outcome Clinical Quality Measure**

Focus Task– Drug Use/Primary Care

- Evaluate existing clinical evidence of effective tools in the Primary Care/General Medical setting for to identification, brief treatment or referral for patients who misuse illegal and prescription drugs
- Evaluate existing clinical evidence of SBIRT tools in the Primary Care/General Medical setting for to identification, brief treatment or referral for patients who misuse illegal and prescription drugs
- Fund clinical research of patient-administered SISQ (Single Item Screening Question (SISQ) for Drug Use (Investigator – Richard Saitz)

Focus Task– Drug Use/Primary Care

■ NOTES:

- Environmental scans performed in support of these tasks will evaluate existing programs to determine if there are available data sources that can be analyzed to contribute to our understanding of the efficacy of SBIRT and related models for DU/PDM
- This work will not lead to development of new Clinical Quality Measures for Drug Use in the term of this contract
- Results of these research activities will be provided to SAMHSA and ONC for future measure development consideration

Focus Domain – Trended Depression Measure

- **Develop a CQM for change in Depression Evaluation scores over time**
- **Considerations:**
 - Meaningful Use Stage 1 Final Rule contains no trended outcome measures


Technical Expert Panel (TEP) Schedule

MITRE

TEP

Subcontractor:
Literature Search

Subcontractor:
R. Saitz, MD



FULL MEETING SCHEDULE and TOPICS

WEEK #	MEETING DAYS	TOPIC
1	OPTION 1: 4/9: 1:00pm-3:00pm OPTION 2: 4/12: 12:30pm–2:30pm	KICK-OFF
2	4/16 3-4:30pm Eastern	Suicide/Trauma – Meeting 1
3	4/23 3-4:30pm Eastern	Autism – Meeting 1
4	4/30 3-4:30pm Eastern	Depression – Meeting 1
5	5/7 3-4:30pm Eastern	Drugs/Alcohol – Meeting 1
6	5/14 3-4:30pm Eastern	Suicide/Trauma – Meeting 2
7	5/22 2:30-4:00pm Eastern TUESDAY	Autism – Meeting 2
8	5/29 3-4:30pm Eastern TUESDAY	Depression – Meeting 2
9	6/4 3-4:30pm Eastern	Drugs/Alcohol – Meeting 2
10	6/11 3-4:30pm Eastern	Suicide/Trauma – Meeting 3
11	6/18 3-4:30pm Eastern <i>*NOTE: Date may be moved to 6/19</i>	Autism – Meeting 3

FOCUS MEETING SCHEDULE and TOPICS

WEEK #	MEETING DAYS	TOPIC
12	6/25 3-4:30pm Eastern	Depression - Meeting 3
13	7/2 3-4:30pm Eastern	Drugs/Alcohol–Meeting 3
14	7/9 3-4:30pm Eastern	Depression
15	7/16 3-4:30pm Eastern	Drugs/Prescription Drug Misuse
16	7/23 3-4:30pm Eastern	Depression
17	7/30 3-4:30pm Eastern	Drugs/Prescription Drug Misuse
18	8/6 3-4:30pm Eastern	Depression
19	8/13 3-4:30pm Eastern	Drugs/Prescription Drug Misuse
20	8/20 3-4:30pm Eastern	Depression
21	8/27 3-4:30pm Eastern	Drugs/Prescription Drug Misuse
22	9/3 3-4:30pm Eastern	Depression
23	9/10 3-4:30pm Eastern	Drugs/Prescription Drug Misuse
24	9/17 3-4:30pm Eastern	Depression
25	9/24 3-4:30pm Eastern	Drugs/Prescription Drug Misuse

Logistics

- Project Web Site: www.healthit.gov/behavioralhealth
- Weekly Meetings Open to Public
- Panelists to receive Outlook Invitations with Meeting Materials attached
- All Meetings include teleconference and webinar access instructions in Outlook Invitation



Questions



Addendum

eMeasure Titles and Descriptions

NQF	Title	Description
0109 CQAIMH	Bipolar Disorder and Major Depression: Assessment for Manic or Hypomanic Behaviors	Percentage of patients treated for depression who were assessed, prior to treatment, for the presence of current and/or prior manic or hypomanic behaviors.
0110 CQAIMH	Bipolar Disorder and Major Depression: Appraisal for Alcohol or Chemical Substance Use	Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use
0111 CQAIMH	Bipolar Disorder: Appraisal for Risk of Suicide	Percentage of patients with bipolar disorder with evidence of an initial assessment that includes an appraisal for risk of suicide.
1385 HRSA/ OHSU	Developmental Screening Using a Parent Completed Screening Tool (Parent report, Children 0-5)	The measure assesses whether the parent or caregiver completed a developmental screening tool meant to identify children at-risk for developmental, behavioral and social delays.
0576 NCQA	Follow-Up After Hospitalization for Mental Illness	percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an Intensive outpatient encounter or partial hospitalization with a mental health practitioner.

(Continued)

eMeasure Titles and Descriptions (cont.)

NQF	Title	Description
1401 NCQA	Maternal Depression Screening	The percentage of children who turned 6 months of age during the measurement year who had documentation of a maternal depression screening for the mother.
1406 NCQA	Risky Behavior Assessment or Counseling by Age 13	Percentage of children with documentation of a risk assessment or counseling for risky behaviors by the age of 13 Years. Four rates are reported: Risk Assessment or Counseling for Alcohol Use, Risk Assessment or Counseling for Tobacco Use, Risk Assessment or Counseling for Other Substance Abuse, Risk Assessment or Counseling for Sexual Activity
1507 NCQA	Risky Behavior Assessment or Counseling by Age 18	Percentage of children with documentation of assessment or counseling for risky behavior. Four rates are reported: assessment or counseling for alcohol use, tobacco use, other substance use, and sexual activity.
0580	Bipolar Antimanic Agent	Percentage of patients with newly diagnosed bipolar disorder who have received at least 1 prescription for a mood-stabilizing agent during the measurement year.

(Continued)

eMeasure Titles and Descriptions (cont.)

NQF	Title	Description
TBD TJC 1661	SUB-1 Alcohol Use Screening	Hospitalized patients 18 years of age and older who are screened during the hospital stay using a validated screening questionnaire for unhealthy alcohol use.
TBD TJC 1663	SUB-2 Alcohol Use Brief Intervention Provided or Offered and SUB-2a Alcohol Use Brief Intervention	The measure is reported as an overall rate which includes all hospitalized patients 18 years of age and older to whom a brief intervention was provided, or offered and refused, and a second rate, a subset of the first, which includes only those patients who received a brief intervention.

MU Stage 2 NPRM Proposed BH Measures

Measure Number	Title and Description	Domain
NQF 0004	Title: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	Clinical Process/ Effectiveness
NQF 0028	Title: Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment, b. Tobacco Cessation Intervention	Population/ Public Health
NQF 0103	Title: Major Depressive Disorder (MDD): Diagnostic Evaluation	Clinical Process/ Effectiveness
NQF 0104	Title: Major Depressive Disorder (MDD): Suicide Risk Assessment	Clinical Process/ Effectiveness
NQF 0105	Title: Anti-depressant Medication Management: (a) Effective Acute Phase Treatment, (b) Effective Continuation Phase Treatment	Clinical Process/ Effectiveness
NQF 0106	Title: Diagnosis of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents	Care Coordination
NQF 0107	Title: Management of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents	Clinical Process/ Effectiveness
NQF 0108	Title: ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication	Clinical Process/ Effectiveness
NQF 0110	Title: Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use	Clinical Process/ Effectiveness
NQF 0112	Title: Bipolar Disorder: Monitoring change in level-of-functioning	Clinical Process/ Effectiveness

(Continued)

MU Stage 2 NPRM Proposed BH Measures (cont.)

Measure Number	Title and Description	Domain
NQF 0710	Title: Depression Remission at Twelve Months	Clinical Process/ Effectiveness
NQF 0711	Title: Depression Remission at Six Months	Clinical Process/ Effectiveness
NQF 0712	Title: Depression Utilization of the PHQ-9 Tool	Clinical Process/ Effectiveness
NQF 1365	Title: Child and Adolescent Major Depressive Disorder: Suicide Risk Assessment	Patient Safety
NQF 1401	Title: Maternal depression Screening	Population/ Public Health
TBD	Title: Depression screening and follow-up assessment using patient self-reported process	Patient and Family Engagement
TBD	Title: Closing the referral loop: receipt of specialist report	Care Coordination
NQF 0024	Title: Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents Description	Population/ Public Health
NQF 0421	Title: Adult Weight Screening and Follow-Up Description	Population/Public Health